Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 1 (1)

Trial Status

Recruiting3

Clinical Trials (3)

Showing 3 of 3 trials
NCT03922555Phase 1RecruitingPrimary

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

NCT05106725Recruiting

Wearable Devices and Biomarkers Project (Healthiomics)

NCT06528912RecruitingPrimary

Standard Follow-up Program Neuro-oncology Patients (SFP Neuro-Oncology)

Showing all 3 trials

Research Network

Activity Timeline